Polygenic risk score prediction of antipsychotic dosage in schizophrenia

Schizophrenia Research
Nuwan C HettigeV De Luca

Abstract

Genetic variants have yet to be identified as reliable predictors of antipsychotic dosage. The purpose of this study is to quantify significant genetic risk variants prioritized from the Psychiatric GWAS Consortium (PGC2) study for schizophrenia as a polygenic score to test our hypothesis that it may represent symptom severity in patients and therefore predict antipsychotic dosage. Antipsychotic medication and dosage were collected in our sample of 83 patients with schizophrenia spectrum disorders of a homogeneous European background. Antipsychotic dosage was standardized according to the Product Monograph (PM%), chlorpromazine equivalents (CPZe), and Defined Daily Dose (DDD). We calculated polygenic risk scores (PRS) for the significant risk loci identified from the PGC2 GWAS to predict dosage using a linear regression model. In our analysis, the PRS showed no significant association with PM%, CPZe, and DDD dosage. Considering symptom severity and overall functioning, our PRS was similarly not significantly associated with Global Assessment of Functioning (GAF) scores. Our results do not provide evidence for a polygenic inheritance of schizophrenia that influences levels of antipsychotic dosage. To the best of our knowledge, t...Continue Reading

References

Nov 21, 1990·JAMA : the Journal of the American Medical Association·D A RegierF K Goodwin
Jun 30, 2000·The American Journal of Psychiatry·M T TsuangS V Faraone
Jul 6, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·P Batel
Feb 21, 2002·Schizophrenia Research·Hélène Verdoux, Jim van Os
Mar 29, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·A Heinz
May 10, 2005·Acta Psychiatrica Scandinavica. Supplementum·R A Bressan, J A Crippa
Nov 10, 2009·Behavior Research Methods·Franz FaulAlbert-Georg Lang
Apr 3, 2010·The American Journal of Psychiatry·David M GardnerRoss J Baldessarini
Nov 19, 2010·Schizophrenia Bulletin·Philip R SzeszkoDelbert G Robinson
Dec 24, 2010·BMC Genomics·Randall C JohnsonStephen J O'Brien
Aug 16, 2013·JAMA Psychiatry·Lena PalaniyappanPaola Dazzan
Jun 26, 2014·Acta Psychiatrica Scandinavica·M TesliO A Andreassen
Jul 25, 2014·Nature·UNKNOWN Schizophrenia Working Group of the Psychiatric Genomics Consortium
Sep 17, 2014·Molecular Psychiatry·R Plomin, I J Deary
Oct 24, 2014·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Sek Won KongUNKNOWN MedSeq Project
May 7, 2015·Journal of Psychopharmacology·Danai Dima, Gerome Breen
May 10, 2015·British Medical Bulletin·John Lally, James H MacCabe

❮ Previous
Next ❯

Citations

Mar 27, 2018·Annual Review of Clinical Psychology·Ryan BogdanArpana Agrawal
Oct 15, 2019·Twin Research and Human Genetics : the Official Journal of the International Society for Twin Studies·Thomas M PiaseckiWendy S Slutske
May 2, 2019·Frontiers in Pharmacology·Antonio VitaMassimo Gennarelli
Apr 12, 2019·Frontiers in Genetics·Daniel Sik Wai HoJustin O'Sullivan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The American Journal of Psychiatry
Marian L HamshereAnita Thapar
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics
N MullinsC M Lewis
Psychiatry and Clinical Neurosciences
Mami FujibayashiToshio Moritani
© 2022 Meta ULC. All rights reserved